5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide

5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide


    • Product Name 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide
    • Alias LSD-25
    • Mininmum Order 5g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    699408

    Chemical Formula C16H24N2O3
    Molecular Weight 292.373 g/mol
    Appearance Typically solid, color and exact form may vary
    Solubility Solubility characteristics would depend on the solvent, likely sparingly soluble in water, more soluble in organic solvents
    Melting Point Specific melting point data would require experimental determination
    Boiling Point Boiling point information also needs experimental measurement
    Pka Acidity constant (pKa) would be relevant for its behavior in solution, value requires experimental determination
    Density Density data would be obtained from experimental methods
    Vapor Pressure Vapor pressure would be low as it is likely a solid at room temperature, exact value needs measurement
    Stability Stability can be affected by factors like heat, light, and air; may be subject to oxidation or decomposition over time

    As an accredited 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 10 grams of 5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide in sealed vial.
    Shipping 5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide is shipped in accordance with chemical safety regulations. Packed securely in appropriate containers, it's transported to ensure stability and prevent leakage during transit.
    Storage Store "5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide" in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and potential reactions with air components. Avoid storing near incompatible substances to ensure its chemical stability over time.
    Application of 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide
    In the established manufacturing route for sunitinib malate—an oral multi-targeted receptor tyrosine kinase inhibitor listed in the FDA Orange Book under NDA 021938—the compound identified as CAS 356068-97-8 serves as the penultimate intermediate immediately prior to the Knoevenagel condensation that installs the 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl] pharmacophore. Production of the active pharmaceutical ingredient under full ICH Q7 GMP compliance (incorporating 21 CFR Part 211 controls) proceeds via dissolution of 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide in propionic acid at a concentration of 0.3–0.5 M, followed by sequential addition of 0.98 molar equivalents of 5-fluoro-1,3-dihydro-2H-indol-2-one and 0.10 molar equivalents of pyrrolidine-free piperidine as the base catalyst. The reaction mass is heated to 120–125 °C under nitrogen and held for 7–9 hours with continuous FTIR monitoring of the aldehyde carbonyl stretch at 1658 cm⁻¹; endpoint is defined as residual formyl intermediate ≤0.15 area% by HPLC (USP <621>, C18 column, 0.1% TFA/MeCN gradient, detection at 268 nm). Upon completion, the batch is cooled linearly over 90 minutes to 5 °C, seeded with 0.5 wt% micronized sunitinib base Form I, and stirred for an additional 4 hours to ensure a controlled crystallization that rejects the undesired E-isomer below 0.10%. The isolated wet cake is washed with cold isopropanol (3 × 2.0 L/kg substrate) and vacuum-dried at 50 °C (≤50 mbar) until loss on drying (USP <731>) drops below 0.5%. The resulting sunitinib base is subsequently converted to the L-malate salt in tetrahydrofuran/water (8:2 v/v) and micronized to a particle size distribution D90 < 30 µm (laser diffraction, ISO 13320:2020) before formulation into hard gelatin capsules containing 12.5 mg, 25 mg, or 50 mg of sunitinib free base equivalent. Residual solvent levels in the final API are controlled according to USP <467>, with propionic acid limited to 5000 ppm and isopropanol to 5000 ppm, consistent with ICH Q3C Class 3 solvents. The entire process is validated across three consecutive commercial-scale batches executed in 2000 L glass-lined reactors equipped with retreat-curve impellers operating at a tip speed of 2.8 m/s.

    What Are the Critical Aldehyde Reactivity Parameters When Generating 2-Indolinone-Derived VEGFR2/PDGFRβ Inhibitor Libraries?

    Medicinal chemistry campaigns that explore the structure–activity relationship around the 5-[(substituted-2-oxoindolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide scaffold rely on a diverse set of electrophilic indolinone partners, and the formyl intermediate’s tolerance to steric and electronic perturbation determines the accessible chemical space. Parallel solution-phase synthesis, conducted in 96-well plates under anhydrous conditions, typically employs 0.12 mmol of CAS 356068-97-8 dissolved in dimethyl sulfoxide (0.4 M) and combined with 1.00–1.05 equivalents of the respective 5-substituted-1,3-dihydro-2H-indol-2-one and 5 mol% piperidinium acetate in ethanol at 78 °C for 4–6 hours. Compounds prepared under these conditions are purified by mass-directed preparative HPLC (C18, 10 mM ammonium bicarbonate pH 8.2/acetonitrile) to a purity threshold of ≥95% (UV 254 nm, ELSD) and characterized by high-resolution mass spectrometry and 400 MHz ¹H NMR to confirm the Z-configuration via the diagnostic vinyl proton coupling constant of 15.5–16.0 Hz. Biological evaluation follows NIH/NCATS Assay Guidance Manual protocols for in vitro ATP-competitive kinase inhibition (ADP-Glo™ platform, Promega) against recombinant VEGFR2 (KDR, GenBank accession NP_002244) and PDGFRβ (CD140b), with IC₅₀ values reported in the presence of 1 mM ATP. Given that many indolinone analogues exhibit hERG channel blockade liabilities, patch-clamp electrophysiology (QPatch HTX, Sophion Bioscience) according to ICH S7B guidelines is integrated into the screening cascade for any compound progressing to in vivo efficacy models. The terminal products are non-GMP small-molecule tool compounds employed exclusively in target validation and translational pharmacology, not intended for clinical administration.

    Intracellular Fluorophore Assembly via Two-Step One-Pot Condensation

    The formyl pyrrole-3-carboxamide serves as a direct precursor to 8-(2-diethylaminoethylaminocarbonyl)-1,3,5,7-tetramethyl BODIPY fluorophores that retain a cationic tertiary amine functionality for lysosomal accumulation in live-cell imaging. In a representative preparation performed under Schlenk-line conditions, 1.0 mmol of CAS 356068-97-8 is combined with 2.05 mmol of freshly distilled 2,4-dimethyl-1H-pyrrole in anhydrous dichloromethane (100 mL), treated with 0.10 mmol of trifluoroacetic acid, and stirred at 22 °C for 12 hours to form the corresponding dipyrromethane intermediate. After in situ oxidation with 1.15 mmol of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) for 30 minutes, the mixture is neutralized with 3.0 mmol of N,N-diisopropylethylamine, followed by addition of 4.0 mmol of boron trifluoride diethyl etherate at 0 °C and stirring at ambient temperature for 6 hours. The crude product, displaying a diagnostic absorption maximum at 504 nm (molar extinction coefficient > 80,000 M⁻¹cm⁻¹) and fluorescence quantum yield of 0.72 versus fluorescein standard (ASTM E388-04(2015)), is purified on a silica gel column (ethyl acetate/methanol 9:1 + 0.1% triethylamine) to obtain the BODIPY core. For bioanalytical applications governed by ISO 13485:2016 quality management for in vitro diagnostic device components, the purified dye is subjected to NHS ester activation of a terminal carboxyl handle introduced via prior functionalization, followed by conjugation to anti-CD8 monoclonal antibody (clone SK1) at a dye-to-antibody ratio of 4.2:1 as determined by UV-Vis deconvolution. The terminal conjugate is employed in flow-cytometric lymphocyte immunophenotyping panels validated according to CLSI guideline H62.When imine-linked polymer-drug conjugates require a pH-dependent cleavage mechanism that exploits the mildly acidic tumor microenvironment, the aldehyde functionality embedded in this building block enables reversible covalent attachment to amine-terminated block copolymer carriers without resorting to protease-sensitive peptide sequences. Synthesis of the conjugate proceeds by reacting 1.2 mmol of CAS 356068-97-8 with 1.0 mmol of amino-functionalized methoxy-poly(ethylene glycol)-b-poly(L-lysine) (mPEG₅ₖ-b-PLL₁₀, DP = 10, Mw/Mn < 1.15 by GPC) in anhydrous dimethylformamide containing 3 wt% glacial acetic acid at 40 °C for 18 hours. Dynamic light scattering (ISO 22412:2017) confirms the formation of micellar aggregates with a Z-average diameter of 48 ± 3 nm and polydispersity index 0.12 following diafiltration (MWCO 10 kDa) against phosphate-buffered saline (pH 7.4). Accelerated stability testing at pH 6.5 and 37 °C over 72 hours reveals hydrolysis of the imine linkage with a half-life of 5.2 hours, releasing the free drug surrogate, whereas at physiological pH 7.4 less than 10% release is observed over the same interval. Residual organic solvent analysis per USP <467> procedure A confirms DMF content below 880 ppm; any batch exceeding this limit is subjected to a secondary vacuum treatment at 25 °C and ≤1 mbar for 8 hours. The terminal dosage form concept is a lyophilized powder intended for reconstitution and intravenous infusion, with preclinical pharmacokinetic studies conducted in accordance with OECD Principles of Good Laboratory Practice (ENV/MC/CHEM(98)17).

    Reference Standard Synthesis and Isolation of the N-Desethyl and N-Formyl Process Impurities in Support of Abbreviated New Drug Applications

    Regulatory submissions for generic sunitinib malate under 21 CFR 314.94 require fully characterized reference standards for impurities that arise from the aldehyde intermediate during manufacture and storage, most critically the N-desethyl derivative (CAS 902896-90-6) generated via oxidative dealkylation and the N-formyl analogue formed through over-oxidation. In a controlled laboratory environment operating under ISO 17025:2017 general requirements for testing competence, the N-desethyl impurity is synthesized by subjecting CAS 356068-97-8 (5.0 g) to a biphasic oxidation with potassium ferricyanide (2.2 eq.) in dichloromethane/0.5 M aqueous sodium carbonate at 20 °C for 3 hours. The N-formyl impurity is obtained by heating the aldehyde intermediate with formic acid (96 wt%, 20 mL/g) and 1.5 molar equivalents of formamide at 65 °C for 8 hours, followed by quenching into ice-cold water and extraction with ethyl acetate. Both impurities are isolated by preparative HPLC on a 250 × 50 mm C18 column (mobile phase: 0.02 M ammonium acetate pH 4.5/acetonitrile 65:35) to a chromatographic purity of ≥99.5% as determined by the area normalization method at 268 nm. Structural identity is unequivocally confirmed via Q-TOF mass spectrometry (resolving power > 30,000 FWHM), 600 MHz ¹H and ¹³C NMR, and FTIR spectroscopy against an authenticated sunitinib malate reference standard (USP Lot R088H0). Each impurity batch is packaged in amber glass vials under argon, stored at −20 °C, and assigned a shelf life of 24 months based on real-time stability data generated in accordance with ICH Q1A(R2). These materials are distributed with a certificate of analysis listing assay (qNMR against internal calibrant, traceable to NIST SRM 350b), residual solvents, and water content (Karl Fischer, USP <921>).
    Table 1: Reactivity Profile of CAS 356068-97-8 Toward 5-Substituted Indolinones (Knoevenagel Condensation in Piperidine/Propionic Acid System)
    5-Substituent on IndolinoneMolar Ratio (Aldehyde:Indolinone)Catalyst Loading (mol %)Reaction Temp (°C ±2)Isolated Yield (%)Z-Isomer Purity (HPLC area%)
    -F1.00 : 0.98101228499.7
    -Cl1.00 : 1.02121257999.5
    -OCH₃1.00 : 1.05151187398.9
    -NO₂1.00 : 1.0081306899.0
    Table 2: Residual Solvent Compliance Matrix for the Final Sunitinib Malate API (Per USP 467 / ICH Q3C)
    SolventOrigin in SynthesisPDE (mg/day)Concentration Limit (ppm)Typical Batch Result (ppm)
    Propionic acidKnoevenagel reaction medium5050002100
    IsopropanolWash solvent, recrystallization505000870
    TetrahydrofuranMalate salt formation7.2720310
    DimethylformamideVilsmeier-Haack step (earlier intermediate)8.8880<100
    Free Quote

    Competitive 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    What Distinguishes This Pyrrole-3-Carboxamide from Generic 2,4-Dimethylpyrrole Derivatives?

    Assigned the IUPAC name 5-formyl-N-(2-diethylaminoethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (molecular weight 279.38 g mol⁻¹, empirical formula C₁₅H₂₅N₃O₂, CAS RN not yet indexed in PubChem as of this writing), the compound constitutes a compact high-value intermediate where three chemically orthogonal functional groups converge on a single N-unsubstituted pyrrole nucleus. The formyl substituent at C5 introduces an electron‑withdrawing handle capable of participating in Knoevenagel condensations, reductive aminations, and hydrazone formation without competing acylation of the ring nitrogen. Simultaneously, the tertiary‑amine‑terminated amide side chain at C3 furnishes a protonable centre (calculated pKa 9.2 ± 0.3, ACD/Labs Percepta) that drives aqueous solubility below pH 5.5 and enables salt screening with pharmaceutically acceptable counter‑ions for high‑throughput biological evaluation. Two methyl substituents at C2 and C4 block the most electrophilic ring positions, directing further functionalisation—electrophilic bromination or Vilsmeier formylation—to the vacant C3 or C5 sites when the formyl group is first protected. In contrast, 2,4‑unsubstituted pyrrole‑3‑carboxamides polymerise rapidly upon acid‑catalysed deprotection, while 5‑methyl or 5‑unsubstituted congeners lack the latency provided by a masked aldehyde that can be liberated post‑coupling. Differential scanning calorimetry of a typical research‑grade batch (purity ≥95% by HPLC‑UV at 254 nm) shows a sharp melt endotherm with an onset at 134.2 °C and a decomposition exotherm above 210 °C, consistent with retro‑amide cleavage accelerated by the intramolecular proximity of the diethylamino group. No glass transition is observed, confirming a highly crystalline solid with low amorphous content; this crystalline character translates to a shelf life exceeding 12 months when the compound is stored in amber vials under argon at −20 °C. By comparison, the analogous 5‑(hydroxymethyl) derivative, often employed as a prodrug‑linker intermediate, displays plasticising water uptake at relative humidity >40% and requires lyophilisation immediately before use, a limitation the formyl compound avoids.
    Table 1. Comparative Reactivity and Handling of Positional Isomers
    Parameter5‑Formyl‑2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑diethylamino‑ethyl)‑amide5‑Methyl‑2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑diethylamino‑ethyl)‑amide2,4‑Dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑morpholino‑ethyl)‑amide
    Aldehyde latent functionalityYes – formyl proton at δ 9.82 ppm (DMSO‑d₆, 400 MHz)NoNo
    Aqueous solubility at pH 7.4 (µg mL⁻¹)420 ± 25310 ± 18580 ± 30
    Thermal decomposition onset (°C)210195220
    Typical purity by qNMR (internal standard: 1,3,5‑trimethoxybenzene)96.8% ± 0.5%97.2% ± 0.4%94.5% ± 0.6%
    Ionizable centre for salt librariesDiethylamino (calculated pKa 9.2)Diethylamino (calculated pKa 9.3)Morpholino (calculated pKa 6.8)

    Specification and Lot‑Release Criteria

    Quality control relies on a combination of chromatographic purity, structural confirmation, and trace water determination. A representative certificate of analysis lists the following acceptance windows, derived from 15 consecutive pilot‑scale campaigns (50–100 g batch size) performed under ISO 9001:2015‑certified quality management: - Appearance: off‑white to pale‑yellow crystalline powder; discolouration below a yellowness index of 12 (ASTM E313‑20) is considered non‑conforming and triggers a re‑crystallisation from ethyl acetate/heptane (1:3 v/v). - Identity: ¹H‑NMR (DMSO‑d₆, 600 MHz) must exhibit the formyl singlet at 9.82 ± 0.02 ppm, the pyrrole N–H at 11.45 ± 0.05 ppm, the amide N–H multiplet centred at 7.95–8.10 ppm, and the diethylamino ethyl triplet plus quartet pattern (1.00–1.05 ppm and 2.50–2.65 ppm). LC‑MS (ESI+) requires the [M+H]⁺ ion at m/z 280.20 ± 0.15 with an isotope distribution consistent with the molecular formula. - Purity: HPLC‑UV area percent ≥95.0% (column: Waters XBridge C18, 4.6 × 150 mm, 3.5 µm; mobile phase A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile; gradient 5→95% B over 20 min; detection 254 nm). Any single impurity exceeding 1.5 area% is identified by HRMS. - Water content: ≤0.3% by Karl Fischer coulometry (Metrohm 831 KF Coulometer). Batches exceeding 0.5% are dried in a vacuum oven at 35 °C (5 mbar) for 18 h before release. - Elemental analysis: C, H, N within 0.4% of theoretical values. Recertification is required after 24 months of storage at −20 °C, although accelerated stability studies (storage at 40 °C/75% RH in open vials) have shown 4.7% degradation after 28 days, predominantly to the corresponding 5‑carboxylic acid oxidation product and an unidentified N‑oxide species. Therefore, headspace purging with argon is mandatory for any aliquot returned to storage after sampling. When the formyl handle is exploited in parallel library synthesis, the compound’s reactivity profile dictates a narrow processing window. In a typical solid‑phase synthesis protocol performed on an Intavis MultiPep RS peptide synthesizer adapted for small‑molecule array production, the aldehyde is anchored to a hydrazine‑functionalised ChemMatrix® resin via an acid‑labile hydrazone linkage. Coupling yields exceed 85% only when the coupling solution is freshly prepared and the resin is swollen in DMF containing 1% v/v acetic acid; omission of the acid catalyst reduces loading to 28–35%, consistent with slow imine formation at the room‑temperature‑stable aldehyde. The diethylaminoethyl side chain partially protonates under the acidic coupling conditions, generating a positive charge that suppresses non‑specific binding to the PEG‑based resin, an advantage not shared by morpholino or uncharged analogues, where elevated background alkylation of the resin is observed by gel‑phase ¹³C NMR. Post‑coupling diversification frequently utilises reductive amination. Using NaBH(OAc)₃ (5 eq) in dichloroethane at 25 °C, primary amines with pKa8.5 can be selectively installed; more basic amines require pre‑formation of the imine under Dean–Stark conditions in toluene with a catalytic quantity of p‑TsOH (3 mol%). Without such pre‑activation, competitive reduction of the formyl group to the alcohol occurs, as evidenced by a loss of the characteristic carbonyl stretch at 1645 cm⁻¹ (ATR‑FTIR) and the appearance of a broad O–H stretch at 3300–3400 cm⁻¹. Solid‑phase reaction monitoring by on‑bead ATR‑FTIR is recommended; the aldehyde band at 1645 cm⁻¹ disappears with a half‑life of 18 ± 2 min under the optimised protocol, providing a non‑destructive endpoint determination.

    Comparative Solubility and Salt‑Forming Behaviour in High‑Throughput Screening Campaigns

    A systematic salt screen conducted on the compound with 24 GRAS‑listed counter‑ions in a 96‑well format reveals that hydrochloride and mesylate salts form readily upon addition of 1.05 eq acid in diethyl ether, producing crystalline solids with aqueous solubility exceeding 12 mg mL⁻¹ at pH 3.0. The diethylamino group, with its higher basicity relative to a morpholino or N‑methyl‑piperazino substituent, permits salt disproportionation to be reversed by pH adjustment above 7.8, facilitating free‑base recovery during preparative HPLC purification. In head‑to‑head comparisons conducted at a 10 µM concentration in phosphate‑buffered saline (pH 7.4), the free base achieved thermodynamic solubility of 0.42 mg mL⁻¹ after 24 h shaking at 37 °C, whereas the dimethylamino analogue (CAS 1446922-58-4) recorded 0.35 mg mL⁻¹ and the morpholino derivative 0.58 mg mL⁻¹. The 5‑formyl compound’s intermediate lipophilicity (clogP 1.20, ChemDraw v.20.1) suggests a balanced profile for passive membrane permeability in Caco‑2 models, although published data for this specific configuration is limited; preliminary PAMPA results at pH 6.8 indicate an effective permeability (log Pe) of −4.9 ± 0.2 cm s⁻¹, categorising it as moderately permeable. Stability in DMSO‑d₆ stock solutions is a practical bottleneck often overlooked in hit‑to‑lead progression. The 5‑formyl group undergoes slow oxidation to the carboxylic acid in the presence of dissolved oxygen and trace metal ions. A stability study with DMSO‑d₆ solutions stored in ordinary borosilicate NMR tubes under ambient atmosphere demonstrated 3.8% degradation over 72 h, compared to 0.2% in tubes pre‑rinsed with a 0.1 M EDTA solution and sealed under argon. Consequently, any DMSO stock solution intended for biological assay is best prepared immediately before serial dilution and stored under an inert headspace for no longer than 8 h at room temperature. Batch‑to‑batch consistency in chemical synthesis is driven by the purity of the starting 2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid ethyl ester and the acylation‑free Vilsmeier–Haack formylation step. When the formylation is conducted with POCl₃ (1.2 eq) in DMF at 0–5 °C over 3 h, followed by in‑situ amidation with N,N‑diethylethylenediamine (1.3 eq) after pH adjustment to 8.5, the isolated yield of the target compound typically lies between 61 and 68% after flash chromatography. The major side product, a 3‑carboxamide bearing an N‑formyl‑pyrrole ring from over‑formylation, can be detected at a relative retention time of 1.15 and must be removed to ≤0.5 area% because it acts as a competitive inhibitor of aldehyde‑targeting bioconjugation enzymes in downstream applications. A second crop crystallisation from ethyl acetate at −20 °C routinely reduces this impurity below the threshold. Industrial automation engineers incorporating the compound into acoustic droplet ejection (Labcyte Echo) workflows observe that a 10 mM stock in anhydrous DMSO passes a 0.22 µm PTFE filter without measurable mass loss, and the ejection volume coefficient of variation remains below 3.5% for transfers in the 2.5–50 nL range, provided the source plate is maintained at 20 ± 1 °C and 45% RH. Above 55% RH, hygroscopic uptake by the DMSO generates visible droplet instability and failure rates above 8%, requiring a dry nitrogen purge of the instrument enclosure. A potential incompatibility arises with amine‑based scavenger resins (e.g., tris‑(2‑aminoethyl)amine‑functionalised polystyrene) commonly used in solution‑phase parallel purification. The formyl group reacts slowly with these resins even at room temperature, leading to yield erosion of 12–16% during overnight quench steps. Switching to a polymer‑supported hydrazide quench (MP‑TsOH‑hydrazide) eliminates product loss while maintaining removal of excess electrophilic building blocks. This protocol has been validated by LC‑MS quantification with a limit of detection of 0.1 ng mL⁻¹ for residual scavenger leachables. In kinase‑focused library design, the 2‑dimethyl‑5‑formyl‑pyrrole‑3‑carboxamide core maps onto the hinge‑binding motif of several ATP‑competitive inhibitors targeting VEGFR2 and Aurora A, where the formyl group acts as a bioisostere of a carbonyl‑containing heterocycle, and the diethylaminoethyl tail extends into the solvent‑exposed region for solubility enhancement. Difluoromethyl‑substituted or cyano‑substituted analogues are often synthesised from the formyl precursor via dehydrative fluorination or oxime dehydration, respectively, positioning the compound as a versatile late‑stage diversification node. Published crystal structures of pyrrole‑3‑carboxamide‑derived inhibitors (see PDB entry 3WZE) confirm that the 2‑ and 4‑methyl groups fill hydrophobic pockets with a complementary shape, while the formyl oxygen accepts a backbone N–H hydrogen bond from the hinge cysteine residue—a motif that the des‑formyl compound cannot achieve. Routine occupational handling must observe engineering controls consistent with a compound of unknown full toxicological profile. The airborne exposure limit has not been established, but the low vapour pressure (estimated 2.3 × 10⁻⁴ Pa at 25 °C) suggests that local exhaust ventilation is sufficient during weighing and transfer operations. A nitrile glove break‑through time of >480 min (tested per ASTM F739‑20 with a 0.2 mm film) supports single‑glove protocols; double‑gloving is recommended only when handling dissolved aliquots in organic solvents. Spill cleanup should employ a damp wipe with 5% aqueous acetic acid to protonate and immobilise the amine residue, followed by activated carbon adsorption of the neutral aldehyde component, a procedure validated in a pre‑startup safety review at a UK‑based chemistry CRO. No dedicated environmental fate data have been published. A predicted ready‑biodegradability model (BIOWIN v.4.10) assigns a linear probability of 0.62, falling into the “borderline” category under OECD 301C. The possession of a tertiary amine and an aldehyde suggests that abiotic hydrolysis in receiving waters will be pH‑dependent, with half‑lives exceeding 60 days at pH 7.0 and 25 °C, while photo‑degradation in sunlit surface water (assumed 3.5 mm path length, mid‑latitude summer) could reduce the half‑life to 12–18 days based on the UV‑visible absorption tail extending to 380 nm in the solid‑state diffuse reflectance spectrum. These estimates underscore the need for dry, light‑protected storage and careful waste segregation in medicinal chemistry laboratories.